



April 15, 2019

Novartis Pharma AG
CH-4002, Basel, Switzerland

Reference: EudraCT 2013-005333-21/ Novartis Protocol ID CACZ885X2202

A multiple-dose, double-blind, placebo-controlled, parallel study to assess the efficacy, safety and tolerability of ACZ885 (Canikumab) in patients with pulmonary sarcoidosis

Trial CACZ885X2202 was cancelled with no patient enrollment and as such, no results will be reported.